Analytical approaches for assaying metallodrugs in biological samples: Recent methodological developments and future trends

Current Drug Metabolism

Volumn 13, Issue 3, 2012, Pages 272-283

  Timerbaev, Andrei ^a   Stürup, Stefan ^b  

^a VERNADSKY INSTITUTE OF GEOCHEMISTRY AND ANALYTICAL CHEMISTRY   (Russian Federation)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Analytical methodology; Bioanalysis; ICP MS; Metallodrugs; Metallomics; Platinum; Ruthenium

Indexed keywords

CISPLATIN; GALLIUM; OXALIPLATIN; RUTHENIUM DERIVATIVE;

ANALYSIS; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BIOASSAY; CAPILLARY ELECTROPHORESIS; CENTRIFUGATION; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG ANALYSIS; DRUG DETERMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSFORMATION; GAS CHROMATOGRAPHY; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LASER SURGERY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METAL BINDING; METHODOLOGY; MOLECULAR WEIGHT; NONHUMAN; PERFORMANCE; PHOTOMETRY; POTENTIOMETRY; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS;

ANIMALS; CHROMATOGRAPHY, LIQUID; CLINICAL LABORATORY TECHNIQUES; DRUG MONITORING; ELECTROPHORESIS, CAPILLARY; HUMANS; MASS SPECTROMETRY; METALS;

EID: 84860517579     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012799320473     Document Type: Article

References (156)

1. Gielen, M.; Tiekink, E. R. T. Eds.; Metallotherapeutic Drugs and Metal-Based Diagnostic Agents, Wiley: New York, 2005.
2. Ronconi, L.; Sadler, P. J. Using coordination chemistry to design new medicines. Coord. Chem. Rev., 2007, 251(13-14), 1633-48.
3. Hannon, M. J. Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology. Pure Appl. Chem., 2007, 79 12, 2243-61.
4. Jakupec, M. A.; Galanski, M.; Arion, V. B.; Hartinger, C. G.; Keppler, B. K. Antitumour metal compounds: More than theme and variations. Dalton Trans., 2008, (2), 183-94.
5. Gianferrara, T.; Bratos, I.; Alessio, E. A categorization of metal anticancer compounds based on their mode of action. Dalton Trans., 2009, (37), 7588-98.
6. Sadler, P. J. Dalton Transaction themed issue of metal anticancer compounds. Dalton Trans., 2009, (48), 10647.
7. Kelland, L. R.; Farrel, N. Eds.; Platinum-Based Drugs in Cancer Therapy, Humana Press: Totawa, NJ, 2000.
8. Todd, R. C.; Lippard, S. J. Inhibition of transcription by platinum antitumor compounds. Metallomics, 2009, 1 4, 280-91.
9. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nature Rev. Cancer, 2007, 7 8, 573-84.
10. Harper, B. W.; Krause-Heuer, A. M.; Grant, M. P.; Manohar, M.; Garbutcheon-Singh, K. B.; Aldrich-Wright, J. R. Advances in platinum chemotherapeutics. Chem. Eur. J., 2010, 16 24, 7064-77.
11. Dyson, P. J.; Sava, G. Metal-based antitumor drugs in the post genomic era. Dalton Trans., 2006, (16), 1929-33.
12. Levina, A.; Mitra, A.; Lay, P. A. Recent developments in ruthenium anticancer drugs, Metallomics, 2009, 1 6, 458-70.
13. Timerbaev, A. R. Advances in developing tris (8-quinolinolato) gallium (III) as an anticancer drug: critical appraisal and prospects. Metallomics, 2009, 1 3, 193-8.
14. Graham, M. A.; Lockwood, G. F.; Greenslade, D.; Brienza, S.; Bayssas, M.; Gamelin, E. Clinical pharmacokinetics of oxaliplatin: A critical review. Clin. Cancer Res., 2000, 6 4, 1205-18.
15. Urien, S.; Lokiec, F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br. J. Clin. Pharmacol., 2004, 57 6, 756-63.
16. Łobiński, R.; Schaumlöffel, D.; Szpunar, J. Mass spectrometry in bioinorganic analytical chemistry. Mass Spectrom. Rev., 2006, 25 2, 255-89.
17. Gammelgaard, B.; Hansen, H. R.; Stürup, S.; Møller, C. The use of inductively coupled plasma mass spectrometry as a detector in drug metabolism studies. Expert Opin. Drug Metab. Toxicol., 2008, 4 9, 1187-207.
18. Brouwers, E. E. M.; Tibben, M.; Rosing, H.; Schnellens, J. H. M.; Beijnen, J. H. The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research. Mass Spectrom. Rev., 2008, 27 2, 67-100.
19. Esteban-Fernández, D.; Moreno-Gordaliza, E.; Cañas, B.; Palacios, M. A.; Gómez-Gómez, M. M. Analytical methodologies for metallomics of antitumor Pt-containing drugs. Metallomics, 2010, 2 1, 19-38.
20. Michalke, B. Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs. J. Trace Elem. Med. Biol., 2010, 24 2, 69-77.
21. Yang, Z., Hou, X.; Jones, B. T. Determination of platinum in clinical samples. Appl. Spectrosc. Rev., 2002, 37 1, 57-88.
22. Barefoot, R. R. Speciation of platinum compounds: a review of recent applications in studies of platinum anticancer drugs. J. Chromatogr. Biomed. Sci. Applic., 2001, 751 2, 205-11.
23. Dowell, J. A.; Sancho, A. R.; Anand, D.; Wolf, W. Noninvasive measurements for studying the tumoral pharmacokinetics of platinum anticancer drugs in solid tumors. Adv. Drug Delivery Rev., 2000, 41 1, 111-26.
24. Greaves, E. D. Heavy element determination in health-related organic matrix materials by total reflection x-ray fluorescence. Adv. X-Ray Anal., 2000, 43, 601-9.
25. Barefoot, R. R., Sample preparation for metal-based drugs. In Comprehensive Analytical Chemistry, Barcelo, D., Ed.; Elsevier: Amsterdam, 2003, 41, pp. 1173-83.
26. Taylor, A.; Branch, S.; Day, M. P.; Patriarca, M.; White, M. Atomic spectrometry update. Clinical and biological materials, foods and beverages. J. Anal. At. Spectrom., 2010, 25 4, 453-92.
27. Caruso, J. A.; Wrobel, K.; Wrobel, K. Recent applications of ICPMS in studies of biological and clinical significance. Curr. Topics Anal. Chem., 2004, 4, 19-33.
28. Gabano, E.; Ravera, M.; Colangelo, D.; Osella, D. Bioinorganic chemistry: the study of the fate of platinum-based antitumour drugs. Curr. Chem. Biol., 2007, 1 3, 278-89.
29. Screnci, D.; McKeage, M. J.; Galettis, P.; Hambley, T. W.; Palmer, B. D.; Baguley, B. C. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br. J. Cancer, 2000, 82 4, 966-72.
30. Morrison, J. G.; White, P.; McDougall, S.; Firth, J. W.; Woolfrey, S. G.; Graham, M. A.; Greenslade, D. Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. J. Pharmaceut. Biomed., 2000, 24 1, 1-10.
31. Sessa, C.; Capri, G.; Gianni, L.; Peccatori, F.; Grasselli, G.; Bauer, J.; Zucchetti, M.; Vigano, L.; Gatti, A.; Minoia, C.; Liati, P.; Van den Bosch, S.; Bernareggi, A.; Camboni, G.; Marsoni, S. Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. Ann. Oncol., 2000, 11 8, 977-83.
32. Filippich, L. J.; Bucher, A. M.; Charles, B. G. Platinum pharmacokinetics in sulphur-crested cockatoos (Cacatua galerita) following single-dose cisplatin infusion. Aust. Vet. J., 2000, 78 6, 406-11.
33. Liu, J.; Kraut, E. H.; Bender, J.; Brooks, R.; Balcerzak, S. P.; Grever, M. R.; Stanley, H.; D'Ambrosio, S.; Gibson-D'Ambrosio, R.; Chan, K. K. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Cancer Chemother. Pharmacol., 2002, 49 5, 367-74.
34. Liu, J.; Kraut, E. H.; Balcerzak, S.; Grever, M.; D'Ambrosio, S.; Chan, K. K. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat. Cancer Chemother. Pharmacol., 2002, 50 6, 445-53.
35. Carr, J. L.; Tingle, M. D.; McKeage, M. J. Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemother. Pharmacol., 2002, 50 1, 9-15.
36. Hann, S.; Koellensperger, G.; Kanitsar, K.; Stingeder, G.; Brunner, M.; Erovic, B.; Müller, M.; Reiter, C. Platinum determination by inductively coupled plasma-sector field mass spectrometry (ICPSFMS) in different matrices relevant to human biomonitoring. Anal. Bioanal. Chem., 2003, 376 2, 198-204.
37. Jamieson, S. M.; Liu, J.; Hsu, T.; Baguley, B. C.; McKeage, M. J. Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity. Br. J. Cancer, 2003, 88 12, 1942-7.
38. Kolb, R. J.; Ghazi, A. M.; Barfuss, D. W. Inhibition of basolateral transport and cellular accumulation of cDDP and N-acetyl-LcysteinecDDP by TEA and PAH in the renal proximal tubule. Cancer Chemother. Pharmacol., 2003, 51 2, 132-8.
39. Siim, B. G.; Lee, A. E.; Shalal-Zwain, S.; Pruijn, F. B.; McKeage, M. J.; Wilson, W. R. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5, 6-dimethylxanthenone-4- acetic acid (DMXAA). Cancer Chemother. Pharmacol., 2003, 51 1, 43-52.
40. Bettinelli, M.; Spezia, S.; Ronchi, A.; Minoia, C. Determination of Pt in biological fluids with ICP-MS: Evaluation of analytical uncertainty. At. Spectrosc., 2004, 25 3, 103-11.
41. Ekborn, A.; Hansson, J.; Ehrsson, H.; Eksborg, S.; Wallin, I.; Wagenius, G.; Laurell, G. High-dose cisplatin with amifostine: ototoxicity and pharmacokinetics. Laryngoscope, 2004, 114 9, 1660-7.
42. Charlier, C.; Kintz, P.; Dubois, N.; Plomteux, G. Fatal overdosage with cisplatin. J. Anal. Toxicol., 2004, 28 2, 138-40.
43. Filippich, L. J.; Charles, B. G.; Sutton, R. H.; Bucher, A. M. Carboplatin pharmacokinetics following a single-dose infusion in sulphurcrested cockatoos (Cacatua galerita). Aust. Vet. J., 2004, 82 6, 366-9.
44. Smit, T.; Snyman, J. R.; Neuse, E. W.; Bohm, L.; Rensburg, C. E. J. Evaluation of cisplatin and a novel platinum polymer conjugate for drug toxicity and drug distribution in mice. Anti-Cancer Drugs, 2005, 16 5, 501-6.
45. Bettinelli, M. ICP-MS determination of Pt in biological fluids of patients treated with antitumor agents: evaluation of analytical uncertainty. Microchem. J., 2005, 79(1-2), 357-65.
46. McDonald, E. S.; Randon, K. R.; Knight, A.; Windebank, A. J. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: A potential mechanism for neurotoxicity. Neurobiol. Dis., 2005, 18 2, 305-13.
47. Royer, B.; Guardiola, E.; Polycarpe, E.; Hoizey, G.; Delroeux, D.; Combe, M.; Chaigneau, L.; Samain, E.; Chauffert, B.; Heyd, B.; Kantelip, J.-P.; Pivot, X. Serum and interperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotheraphy: influence of protein binding. Anti-Cancer Drugs, 2005, 16 9, 1009-16.
48. Brouwers, E. M. E.; Tibben, M.; Rosing, H.; Hillebrand, M. J. X.; Joerger, M.; Schellens, J. H. M.; Beijnen, J. H. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. J. Mass Spectrom., 2006, 41 9, 1186-94.
49. Lardinois, D.; Jung, F. J.; Opitz, I.; Rentsch, K.; Latkoczy, C.; Vuong, V.; Varga, Z.; Rousson, V.; Gunther, D.; Bodis, S.; Stahel, R.; Weder, W. Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma. J. Thorac. Cardiovasc. Surg., 2006, 131 3, 697-703.
50. Mandal, R.; Sawyer, M. B.; Li, X.-F., Mass spectrometry of hemoglobinoxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses. Rapid Commun. Mass Spectrom., 2006, 20 17, 2533-8.
51. Turci, R.; Minoia, C. Residual hazard assessment related to handling of antineoplastic drugs: Safety system evolution and quality assurance of analytical measurement. Ann. New York Acad. Sci., 2006, 1076, 649-56.
52. Esteban-Fernandez, D.; Gomez-Gomez, M. M.; Cañas, B.; Verdaguer, J. M.; Ramirez, R.; Palacios, M. A. Speciation analysis of platinum antitumoral drugs in impacted tissues. Talanta, 2007, 72 2, 768-73.
53. Pohlen, U.; Rieger, H.; Meyer, B. T.; Loddenkemper, C.; Buhr, H. J.; Heitland, P.; Koester, H. D.; Schneider, P. Chemoembolization of lung metastases - Pharmacokinetic behaviour of carboplatin in a rat model. Anticancer Res., 2007, 27 2, 809-15.
54. Royer, B.; Delroeux, D.; Guardiola, E.; Combe, M.; Hoizey, G.; Montange, D.; Kantelip, J.-P.; Chauffert, B.; Heyd, B.; Pivot, X. Improvement in intraperotoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. Cancer Chemother. Pharmacol., 2008, 61 3, 415-21.
55. Bekaii-Saab, T.; Liu, J.; Chan, K. K.; Balcerzak, S. P.; Ivy, P. S.; Grever, M. R.; Kraut, E. H. A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors. Clin. Cancer Res., 2008, 14 11, 3434-40.
56. Esteban-Fernandez, D.; Verdaguer, J. M.; Ramirez-Camacho, R.; Palacios, M. A.; Gomez-Gomez, M. M. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration. J. Anal. Toxicol., 2008, 32 2, 140-6.
57. Brouwers, E. M. E.; Tibben, M.; Pluim, D.; Rosing, H.; Boot, H.; Cats, A.; Schellens, J. H. M.; Beijnen, J. H. Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin. Anal. Bioanal. Chem., 2008, 391 2, 577-85.
58. Brouwers, E. M. E.; Huitema, A. D. R.; Beijnen, J. H.; Schellens, J. H. M., Long-tem platinum retention after treatment with cispaltin and oxaliplatin, BMC Clin. Pharmacol., 2008, 8 7, 1-10.
59. Royer, B.; Jullien, V.; Guardiola, E.; Heyd, B.; Chauffert, B.; Kantelip, J.-P.; Pivot, X. Population pharmacokinetics and dosing recommendations for cisplatin during interperitoneal peroperative administration. Clin. Pharmacokinet., 2009, 48 3, 169-80.
60. Falta, T.; Koellensperger, G.; Standler, A.; Buchberger, W.; Mader, R. M.; Hann, S. Quantification of cisplatin, carboplatin and oxaliplatin in spiked human plasma samples by ICP-SFMS and hydrophilic interaction liquid chromatography (HILIC) combined with ICP-MS detection. J. Anal. At. Spectrom., 2009, 24 10, 1336-42.
61. Guardiola, E.; Chauffert, B.; Delroeux, D.; Royer, B.; Heyd, B.; Combe, M.; Benoit, L.; Causeret, S.; Demarchi, M.; Magnin, G.; Mayer, F.; Tixier, H.; Pivot, X. Interoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study. Anti-Cancer Drugs, 2010, 21 3, 320-5.
62. Janssens, T.; Brouwers, E. M. E.; de Vos, J. P.; Schellens, J. H. M.; Beijnen, J. H. Determination of platinum originating from carboplatin in canine sebum and cerumen by inductively coupled plasma mass spectrometry. J. Pharmaceut. Biomed. Anal., 2011, 54 2, 395-400.
63. Wang, X.; Yin, X.; Cheng, H. Microflow injection chemiluminescence system with spiral microchannel for the determination of cisplatin in human serum. Anal. Chim. Acta, 2010, 678 2, 135-9.
64. Brouwers, E. M. E.; Tibben, M.; Rosing, H.; Schellens, J. H. M.; Beijnen, J. H. Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry. Rapid Commun. Mass Spectrom., 2007, 21 9, 1521-30.
65. Miles, D. R.; Mesfin, M.; Mody, T. D.; Stiles, M.; Lee, J.; Fiene, B.; Denis, B.; Boswell, G. W. Validation and use of three complementary analytical methods (LC-FLS, LC-MS/MS and ICP-MS) to evaluate the pharmacokinetics, biodistribution and stability of motexafin gadolinium in plasma and tissues. Anal. Bioanal. Chem., 2006, 385 2, 345-56.
66. Stürup, S. Application of HR-ICP-MS for the simultaneous measurement of zinc isotope ratios and total zinc content in human samples. J. Anal. At. Spectrom., 2000, 15 4, 315-21.
67. Pozebon, D.; Dressler, V. L.; Matusch, A.; Becker, J. S. Monitoring of platinum in a single hair by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) after cisplatin treatment for cancer. Int. J. Mass Spectrom., 2008, 272 1, 57-62.
68. Zoriy, M.; Matusch, A.; Spruss, T.; Becker, J. S. Laser ablation inductively coupled plasma mass spectrometry for imaging of copper, zinc, and platinum in thin sections of a kidney from a mouse treated with cis-platin. Int. J. Mass Spectrom., 2007, 260(2-3), 102-6.
69. Massari, C.; Brienza, S.; Rotarski, M.; Gastiaburu, J.; Misset, J.-L.; Cupissol, D.; Alafaci, E.; Dutertre-Catella, H.; Bastian, G. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother. Pharmacol., 2000, 45 2, 157-64.
70. Cocchietto, M.; Salerno, G.; Alessio, E.; Mestroni, G.; Sava, G. Fate of the antimetastatic ruthenium complex ImH [trans-RuCl4 (DMSO) Im] after i.v. treatment in mice. Anticancer Res., 2000, 20(1A), 197-202.
71. Meerum Terwogt, J. M.; Tibben, M. M.; Welbank, H.; Schellens, J. H. M.; Beijnen, J. H. Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry. Fresenius J. Anal. Chem., 2000, 366 3, 298-302.
72. Gu, X.; Chen, X.-J.; Yang, J.; Li, Y.-P.; Zhu, W.-B. Determination of concentration in body of platinum-based anti-cancer drugs by electrothermal atomic absorption spectroscopy. Zhongguo Yaoke Daxue Xuebao, 2000, 31 3, 213-7.
73. Liao, Y.; He, F.; Li, A.; Ni, Z., Direct determination of platinum in urine by electrothermal atomic absorption spectrometry. Am. Clin. Lab., 2000, 19 7, 14-5.
74. Tokunaga, Y.; Nakashima, M.; Sasaki, H.; Tomiyama, N.; Nakashima, M. N.; Ichikawa, M.; Kaminogo, M.; Shibata, S. Local distribution into brain tumor and pharmacokinetics of 4-pyridoxate diammine hydroxy platinum, a novel cisplatin derivative, after intracarotid administration in rats with 9L malignant glioma: simultaneous brain microdialysis study. Biol. Pharm. Bull., 2000, 23 12, 1491-6.
75. Larena, M. G.; Martinez-Diez, M. C.; Monte, M. J.; Dominguez, M. F.; Pascual, M. J.; Marin, J. J. G. Liver organotropism and biotransformation of a novel platinum-ursodeoxycholate derivative, Bamet-UD2, with enhanced antitumor activity. J. Drug Target, 2001, 9 3, 185-200.
76. Vouillamoz-Lorenz, S.; Bauer, J.; Lejeune, F.; Decosterd, L. A., Validation of an AAS method for the determination of platinum in biological fluids from patients receiving the oral platinum derivative JM216. J. Pharm. Biomed. Anal, 2001, 25(3-4), 465-75.
77. Hanada, K.; Nishijima, K.; Ogata, H.; Atagi, S.; Kawahara, M. Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltrated platinum and total platinum. Jpn. J. Clin. Oncol., 2001, 31 5, 179-84.
78. Crul, M.; van den Bongard, H. J. G. D.; Tibben, M. M.; van Tellingen, O.; Sava, G.; Schellens, J. H. M.; Beijnen, J. H. Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry. Fresenius J. Anal. Chem., 2001, 369 5, 442-5.
79. Webster, L. K.; Ellis, A. G.; Apicella, C.; Deacon, G. B. A typical pharmacokinetics and excretion of new platinum analogues in rodents. Cancer Chemother. Pharmacol., 2002, 49 1, 87-92.
80. Tibben, M. M.; Rademaker-Lakhai, J. M.; Rice, J. R.; Stewart, D. R.; Schellens, J. H. M.; Beijnen, J. H. Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl) methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomicabsorption spectrometry. Anal. Bioanal. Chem., 2002, 373(4-5), 233-6.
81. Vouillamoz-Lorenz, S.; Buclin, T.; Lejeune, F.; Bauer, J.; Leyvraz, S.; Decosterd, L. A., Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days. Anticancer Res., 2003, 23(3C), 2757-65.
82. Ishibashi, T.; Yano, Y.; Oguma, T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br. J. Clin. Pharmacol., 2003, 56 2, 205-13.
83. Merkel, U.; Wedding, U.; Roskos, M.; Höffken, K.; Hoffmann, A. Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: A pilot investigation with preliminary results. Exp. Toxic. Pathol., 2003, 54(5-6), 475-9.
84. Delord, J.-P.; Umlil, A.; Guimbaud, R.; Grégoire, N.; Lafont, T.; Canal, P.; Bugat, R.; Chatelut, E. Population pharmacokinetics of oxaliplatin. Cancer Chemother. Pharmacol., 2003, 51 2, 127-31.
85. Bastian, G.; Barrail, A.; Urien, S. Population pharmacokinetics of oxaliplatin in patients with metastatic cancer. AntiCancer Drugs, 2003, 14 10, 817-24.
86. Cermanova, J.; Chladek, J.; Soval, P.; Kroutil, A.; Semerad, M.; Berankova, Z.; Siroky, P.; Surova, I. Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine] amminedichloroplatinum [IV]) in pigs. Meth. Find. Exp. Clin. Pharmacol., 2004, 26 9, 679-85.
87. Rademaker-Lakhai, J. M.; van den Bongard, D.; Pluim, D.; Beijnen, J. H.; Schellens, J. H. M. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororu-thenate, a novel ruthenium anticancer agent. Clin. Cancer Res. 2004, 10 11, 3717-27.
88. Urien, S.; Brain, E.; Bugat, R.; Pivot, X.; Lochon, I.; Vo Van, M.-L.; Vauzelle, F.; Lokiec, F. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemoth. Pharmacol., 2005, 55 1, 55-60.
89. Brouwers, E. E. M.; Tibben, M. M.; Joerger, M.; van Tellingen, O.; Rosing, H.; Schellens, J. H. M.; Beijnen, J. H. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphitefurnace atomic-absorption spectrometry. Anal. Bioanal. Chem., 2005, 382 7, 1484-90.
90. Yonemori, K.; Katsumata, N.; Yamamoto, N.; Kasamatsu, T.; Yamada, T.; Tsunematsu, R.; Fujiwara, Y. A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinumcontaining chemotherapy. Cancer, 2005, 104 6, 1204-12.
91. Bos, A. M. E.; De Vos, F. Y. F. L.; De Vries, E. G. E.; Beijnen, J. H.; Rosing, H.; Mourits, M. J. E.; Van der Zee, A. G. J.; Gietema, J. A.; Willemse, P. H. B. A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. Eur. J. Cancer, 2005, 41 4, 539-48.
92. Hofheinz, R.-D.; Dittrich, C.; Jakupec, M. A.; Drescher, A.; Jaehde, U.; Gneist, M.; Graf v. Keyserlingk, N.; Keppler, B. K.; Hochhaus, A. Early results from a phase I study on orally administered tris (8-quinolinolato) gallium (III) (FFC11, KP46) in patients with solid tumors - a CESAR study. Int. J. Clin. Pharmacol. Therapeut., 2005, 43 12, 590-1.
93. Goodisman, J.; Souid, A.-K. J. Constancy in integrated cisplatin plasma concentrations among pediatric patients. J. Clin. Pharmacol., 2006, 46 4, 443-8.
94. Kroep, J. R.; Smit, E. F.; Giaccone, G.; Van der Born, K.; Beijnen, J. H.; Van Groeningen, C. J.; Van der Vijgh, W. J. F.; Postmus, P. E.; Pinedo, H. M.; Peters, G. J. Pharmacology of the paclitaxelcisplatin, gemcitabine- cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer. Cancer Chemother. Pharmacol., 2006, 58 4, 509-16.
95. Hanada, K.; Asano, K.; Nishimura, T.; Chimata, T.; Matsuo, Y.; Tsuchiya, M.; Ogata, H. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumor derivatives cisplatin, carboplatin and nedaplatin in rats. J. Pharm. Pharmacol., 2008, 60 3, 317-22.
96. Selting, K.; Waldrep, J. C.; Reinero, C.; Branson, K.; Gustafson, D.; Kim, D. Y.; Henry, C.; Owen, N.; Madsen, R.; Dhand, R. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter. J. Aerosol Med. Pulm. Drug Deliv., 2008, 21 3, 255-68.
97. Yamada, Y.; Ikuta, Y.; Nosaka, K.; Miyanari, N.; Hayashi, N.; Mitsuya, H.; Baba, H., Successful treatment of cisplatin overdose with plasma exchange. Case Rep. Med., 2010, article ID 802312.
98. Najafi, N. M.; Shahparvizi, S.; Rafati, H.; Ghasemi, E.; Alizadeh, R. Preconcentration and determination of ultra-traces of platinum in human serum using the combined electrodeposition-electrothermal atomic absorption spectroscopy (ED-ETAAS) and chemometric method. J. Pharm. Biomed. Anal., 2010, 53 1, 58-61.
99. Van Calsteren, K.; Verbesselt, R.; Ottevanger, N.; Halaska, M.; Heyns, L.; Van Bree, R.; De Bruijn, E.; Chai, D.; Delforge, M.; Noens, L.; Renard, V.; Witteveen, E.; Rob, L.; De Hoon, J.; Amant, F. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet. Gynecol. Scand., 2010, 89 10, 1338-45.
100. Da Costa Junior, A. C.; Vieira, M. A.; Luna, A. S.; De Campos, R. C. Determination of platinum originated from antitumoral drugs in human urine by atomic absorption spectrometric methods. Talanta, 2010, 82 5, 1647-53.
101. Gietema, J. A.; Meinardi, M. T.; Messerschmidt, J.; Gelevert, T.; Alt, F.; Uges, D. R. A.; Sleijfer, D. T. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet, 2000, 355 9209, 1075-6.
102. Gerl, A.; Schierl, R. Urinary excretion of platinum in chemotherapytreated long-term survivors of testicular cancer. Acta Oncol., 2000, 39 4, 519-22.
103. Gelevert, T.; Messerschmidt, J.; Meinardi, M. T.; Alt, F.; Gietema, J. A.; Franke, J.-P.; Sleijfer, D. T.; Uges, D. R. A. Adsorptive voltametry to determine platinum levels in plasma from testicular cancer patients treated with cisplatin, Therapeutic Drug Monit., 2001, 23 2, 169-73.
104. Voinea, C.; Ciucu, A.; Ciucu, C.; Voiculet, N. Affinity biosensor for antitumoral drugs determination. Roum. Biotechnol. Lett., 2003, 8 1, 1075-82.
105. Greaves, E. D.; Parra, L. M. M.; Rojas, A.; Sajo-Bohus, L. Determination of platinum levels in serum and urine samples from pediatric cancer patients by TXRF. X-Ray Spectrom., 2000, 29 5, 349-53.
106. Greaves, E. D.; Angeli-Greaves, M.; Jaehde, U., Drescher, A.; von Bohlen, A., Rapid determination of platinum plasma concentrations of chemotherapy patients using total reflectance x-ray fluorescence. Spectrochim. Acta B, 2006, 61 B (10-11), 1194-200.
107. Greaves, E. D.; Angeli-Greaves, M.; Barros, H.; Bermudez, J.; Sajo-Bohus, L. X-ray spectroscopy for quality control of chemotherapy drugs. AIP Conf. Proc., 2007, 947, 31-4.
108. Rietz, B.; Heydorn, K.; Krarup-Hansen, A. The determination of platinum in tissue of different human organs by means of neutron activation analysis. Trace Elem. Electrolyt., 2002, 19 1, 38-41.
109. 3-salicylaldehyde furfuralhydrazone. Anal. Bioanal. Chem., 2006, 384 3, 769-73.
110. Allain, P.; Heudi, O.; Cailleux, A.; Le Bouil, A.; Larra, F.; Boisdron-Celle, M.; Gamelin, E. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab. Dispos., 2000, 28 11, 1379-84.
111. Haraguchi, H.; Ohshima, T.; Matsuura, H.; Hasegawa, T. Speciation of bio-trace elements and drug analysis of serum by surfactantmediated HPLC/ICP-MS. Biomed. Res. Trace Elem., 2001, 12 2, 128-40.
112. Carr, J. L.; Tingle, M. D.; McKeage, M. J. Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemother. Pharmacol., 2002, 50 1, 9-15.
113. Burns, R. B.; Gray, D. J. Conventional and chromatographic ICPMS analysis of cisplatin and carboplatin in plasma and plasma ultrafiltrate. In Plasma Source Mass Spectrom. Applic. Emerging Technol., Holland, G.; Tanner, S. D., Eds., The Royal Society of Chemistry: Cambridge, 2003, pp. 74-81.
114. Smith, C. J.; Wilson, I. D.; Abou-Shakra, F.; Payne, R.; Parry, T. C.; Sinclair, P.; Roberts, D. W. A comparison of the quantitative methods for the analysis of the platinum-containing anticancer drug {cis-[amminedichloro (2-methylpyridine)]-platinum (II)} (ZD0473) by HPLC coupled to either a triple quadrupole mass spectrometer or an inductively coupled plasma mass spectrometer. Anal. Chem., 2003, 75 6, 1463-9.
115. Vacchina, V.; Torti, L.; Allievi, C.; Łobiński, R. Sensitive speciesspecific monitoring of a new triplatinum anti-cancer drug and its potential related compounds in spiked human plasma by cationexchange HPLC-ICP-MS. J. Anal. At. Spectrom., 2003, 18 8, 884-90.
116. Sulyok, M.; Hann, S.; Hartinger, C. G.; Keppler, B. K.; Stingeder, G.; Koellensperger, G. Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium (III) compound with plasma proteins. J. Anal. At. Spectrom., 2005, 20 9, 856-63.
117. Gray, D. J.; Burns, R.; Brunswick, P.; Le Huray, J.; Chan, W.; Mast, M.; Allamneni, K.; Sreedharan, S. Application of ICPMS and chromatography based ICPMS to studies of metal speciation and metal-protein binding in bioanalysis. Spec. Publ. - Royal Soc. Chem., 2005, 301, 43-58.
118. Bell, D. N.; Liu, J. J.; Tingle, M. D.; McKeage, M. J. Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry. J. Chromatogr. B, 2006, 837(1-2), 29-34.
119. Mandal, R.; Sawyer, M. B.; Li, X.-F. Mass spectrometry of hemoglobinoxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses. Rapid Commun. Mass Spectrom., 2006, 20 17, 2533-8.
120. Xie, R. M.; Johnson, W.; Rodriguez, L.; Gounder, M.; Hall, G. S.; Buckley, B. A study of the interactions between carboplatin and blood plasma proteins using size exclusion chromatography coupled to inductively coupled plasma mass spectrometry. Anal. Bioanal. Chem., 2007, 387 8, 2815-22.
121. Esteban-Fernandez, D.; Montes-Bayon, M.; Gonzalez, E. B.; Gomez, M. M. G.; Palacios, M. A.; Sanz-Medel, A. Atomic (HPLCICP-MS) and molecular mass spectrometry (ESI-Q-TOF) to study cis-platin interactions with serum proteins. J. Anal. At. Spectrom., 2008, 23 3, 378-84.
122. Smith, C. J.; Wilson, I. D.; Abou-Shakra, F.; Payne, R.; Grisedale, H.; Long, A.; Roberts, D.; Malone, M. Analysis of a [14C] labelled platinum anticancer compound in dosing formulations and urine using a combination of HPLC-ICPMS and flow scintillation counting. Chromatographia, 2002, 55(Suppl.), S151-5.
123. Hann, S.; Koellensperger, G.; Stefanka, Z.; Stingeder, G.; Fürhacker, M.; Buchberger, W.; Mader, R. M. Application of HPLC-ICP-MS to speciation of cisplatin and its degradation products in water containing different chloride concentrations and human urine. J. Anal. At. Spectrom., 2003, 18 11, 1391-5.
124. Koellensperger, G.; Hann, S. Ultra-fast HPLC-ICP-MS analysis of oxaliplatin in patient urine. Anal. Bioanal. Chem., 2010, 397 1, 401-6.
125. Garcia-Sar, D.; Montes-Bayon, M.; Gonzalez, E. B.; Sierra, L. M.; Aguado, L.; Comendador, M. A.; Koellensperger, G.; Hann, S.; Sanz-Medel, A. Quantitative profiling of in vivo generated cisplatin-DNA adducts using different isotope dilution strategies. Anal. Chem., 2009, 81 23, 9553-60.
126. Sar, D. G.; Montes-Bayon, M.; Ortiz, L. A.; Blanc-Gonzalez, E.; Sierra, L. M.; Sanz-Medel, A. In vivo detection of DNA adducts induced by cisplatin using capillary HPLC-ICP-MS and their correlation with genotoxic damage in Drosophila melanogaster. Anal. Bioanal. Chem., 2008, 390 1, 37-44.
127. Timerbaev, A. R.; Hartinger, C. G.; Aleksenko, S. S.; Keppler, B. K. Interactions of antitumor metallodrugs with serum proteins: Advances in characterization using modern analytical methodology, Chem. Rev., 2006, 106 6, 2224-48.
128. Esteban-Fernandez, D.; Gomez-Gomez, M. M.; Cañas, B.; Verdaguer, J. M.; Ramirez, R.; Palacios, M. A. Speciation analysis of platinum antitumoral drugs in impacted tissues. Talanta, 2007, 72 2, 768-73.
129. Esteban-Fernandez, D.; Verdaguer, J. M.; Ramirez-Camacho, R.; Palacios, M. A.; Gomez-Gomez, M. M. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration. J. Anal. Toxicol., 2008, 32 2, 140-6.
130. Gammelgaard, B.; Jensen, B. P. Application of inductively coupled plasma mass spectrometry in drug metabolism studies. J. Anal. At. Spectrom., 2007, 22 3, 235-49.
131. Esteban-Fernandez, D.; Cañas, B.; Pizarro, I.; Palacios, M. A.; Gomez-Gomez, M. M. SEC-ICP-MS and ESI-MS as tools to study the interaction between cisplatin and cytosolic biomolecules. J. Anal. At. Spectrom., 2007, 22 9, 1113-21.
132. Hann, S.; Falta, T.; Boeck, K.; Sulyok, M.; Koellensperger, G. Online fast column switching SEC × IC separation combined with ICPMS detection for mapping metallodrug-biomolecule interaction. J. Anal. At. Spectrom., 2010, 25 6, 861-6.
133. Tran, M. Q. T.; Nygren, Y.; Lundin, C.; Naredi, P.; Björn, E. Evaluation of cell lysis methods for platinum metallomic studies of human malignant cells. Anal. Biochem., 2010, 396 1, 76-82.
134. Oe, T.; Tian, Y.; O'Dwyer, P. J.; Roberts, D. W.; Malone, M. D.; Bailey, C. J.; Blair, I. A. A validated liquid chromatography/tandem mass spectrometry assay for cis-amminedichloro (2-methylpyridine) platinum (II) in human plasma ultrafiltrate. Anal. Chem., 2002, 74 3, 591-9.
135. Guo, P.; Li, S.; Gallo, J. M., Determination of carboplatin in plasma and tumor by high-performance liquid chromatography-mass spectrometry. J. Chromatogr. B, 2003, 783 1, 43-52.
136. Oe, T.; Tian, Y.; O'Dwyer, P. J.; Roberts, D. W.; Bailey, C. J.; Blair, I. A. Determination of the platinum drug cis-amminedichloro (2-methylpyridine) platinum (II) in human urine by liquid chromatographytandem mass spectrometry. J. Chromatogr. B, 2003, 792 2, 217-7.
137. Kahakachchi, C. L.; Moore, D. A. Identification and characterization of gadolinium (III) complexes in biological tissue extracts. Metallomics, 2010, 2 7, 490-7.
138. Verschraagen, M.; van der Born, K.; Zwiers, T. H. U.; van der Vijgh, W. J. F. Simultaneous determination of intact cisplatin and its metabolite monohydrated cisplatin in human plasma. J. Chromatogr. B, 2002, 772 2, 273-81.
139. Shord, S. S.; Bernard, S. A.; Lindley, C.; Blodgett, A.; Mehta, V.; Churchel, M. A.; Poole, M.; Pescatore, S. L.; Luo, F. R.; Chaney, S. G. Oxaliplatin biotransformation and pharmacokinetics: A pilot study to determine the possible relationship to neurotoxicity. Anticancer Res., 2002, 22 4, 2301-9.
140. Zufía, L.; Aldaz, A.; Castellanos, C.; Giráldez, J. Simple and rapid determination of carboplatin in plasma by high-performance liquid chromatography. Error pattern and application to clinical pharmacokinetic studies. J. Chromatogr. Biomed. Sci. Applic., 2001, 764(1-2), 457-64.
141. Kim, R.; Tanabe, K.; Inoue, H.; Toge, T., Mechanism (s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma. Int. J. Oncol., 2002, 20 3, 549-55.
142. Ehrsson, H.; Wallin, I., Liquid chromatographic determination of oxaliplatin in blood using post-column derivatization in a microwave field followed by photometric detection. J. Chromatogr. B, 2003, 795 2, 291-4.
143. Khuhawar, M. Y.; Arain, G. M. Liquid chromatographic determination of cis-platin as platinum (II) in pharmaceutical preparation, serum and urine samples of cancer patients. Talanta, 2005, 66 1, 34-9.
144. Lopez-Florez, A.; Jurado, R.; Garcia-Lopez, P. A high-performance liquid chromatographic assay for determination of cisplatin in plasma, cancer cell, and tumor samples. J. Pharmacol. Toxicol. Meth., 2005, 52 3, 366-72.
145. Lanjwani, S. N.; Zhu, R.; Khuhawar, M. Y.; Ding, Z. High performance liquid chromatographic determination of platinum in blood and urine samples of cancer patients after administration of cisplatin drug using solvent extraction and N, N'-bis (salicylidene) - 1, 2-propanediamine as complexation reagent. J. Pharm. Biomed. Anal., 2006, 40 4, 833-9.
146. Timerbaev, A. R.; Hartinger, C. G.; Keppler, B. K. Metallodrug research and analysis using capillary electrophoresis. Trends Anal. Chem., 2006, 25 9, 868-75.
147. Timerbaev, A. R.; Keppler, B. K. Capillary electrophoresis of metal-based drugs. Anal. Biochem., 2007, 369 1, 1-7.
148. Hartinger, C. G.; Keppler, B. K. Capillary electrophoresis in anticancer metallodrug research - an update. Electrophoresis, 2007, 28 19, 3436-46.
149. Foteeva, L. S.; Timerbaev, A. R. Application of capillary electrophoresis to the analysis of metal-containing pharmaceuticals. J. Anal. Chem., 2009, 64 12, 1206-13.
150. Møller, C.; Stürup, S.; Hansen, R.; Gammelgaard, B. Comparison of two CE-ICP-MS interfaces and quantitative measurements of carboplatin in plasma samples using an internal standard. J. Anal. At. Spectrom., 2009, 24 9, 1208-12.
151. Groessl, M.; Hartinger, C. G.; Polec-Pawlak, K.; Jarosz, M.; Keppler, B. K. Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma. Electrophoresis, 2008, 29 10, 2224-32.
152. Abramski, J. K.; Foteeva, L. S.; Pawlak, K.; Timerbaev, A. R.; Jarosz, M. A versatile approach for assaying in vitro metallodrug metabolism using CE hyphenated with ICP-MS. Analyst., 2009, 134 10, 1999-2002.
153. Bytzek, A. K.; Enyedy, E. A.; Kiss, T.; Keppler, B. K.; Hartinger, C. G. Biodistribution of anti-diabetic Zn (II) complexes in human serum and in vitro protein-binding studies by means of CZE-ICPMS. Electrophoresis, 2009, 30 23, 4075-82.
154. Künnemeyer, J.; Terborg, L.; Nowak, S.; Brauckmann, C.; Telgmann, L.; Albert, A.; Tokmak, F.; Krämer, B. K.; Günsel, A.; Weismüller, G. A.; Karst, U. Quantification and excretion kinetics of a magnetic resonance imaging contrast agent by capillary electrophoresismass spectrometry. Electrophoresis, 2009, 30 10, 1766-73.
155. Huang, Z.; Timerbaev, A. R.; Keppler, B. K.; Hirokawa, T. Determination of cisplatin and its hydrolytic metabolite in human serum by capillary electrophoresis techniques. J. Chromatogr. A, 2006, 1106(1-2), 75-9.
156. Laghari, A. J.; Khuhawar, M. Y.; Zardari, L. A.; Bhatti, A. G. GC determination of cisplatin in serum and urine of cancer patients after chemotherapy as platinum (II) pyrrolidinedithiocarbamate chelate. Chromatographia, 2008, 67(9/10), 749-54.